Suppr超能文献

缬更昔洛韦二级预防在实体器官移植受者中预防复发性巨细胞病毒病的作用。

Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients.

机构信息

Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center and Tufts University School of Medicine.

Institute for Clinical Research and Health Policy Studies, Tufts Medical Center.

出版信息

Clin Infect Dis. 2017 Nov 29;65(12):2000-2007. doi: 10.1093/cid/cix696.

Abstract

BACKGROUND

Cytomegalovirus (CMV) is a major contributor to morbidity and mortality in solid organ transplant recipients (SOTRs). Ganciclovir and valganciclovir are highly effective antiviral drugs with a well-established role in primary prophylaxis and treatment of CMV disease. Our objective in this study was to examine the effect of secondary prophylaxis (SP) on the risk of relapse in SOTRs following an episode of CMV disease.

METHODS

We performed a retrospective cohort study of SOTRs from 1995 to 2015 and used propensity score-based inverse probability of treatment weighting methodology to control for confounding by indication. A weighted Cox model was created to determine the effect of SP on time to relapse within 1 year of treatment completion.

RESULTS

Fifty-two heart, 34 liver, 79 kidney, and 5 liver-kidney transplant recipients who completed treatment for an episode of CMV infection/disease were included. A total of 120 (70.6%) received SP (median duration, 61 days; range, 5-365) and 39 (23%) relapsed. SP was protective against relapse from 0 to 6 weeks following treatment completion (hazard ratio [HR], 0.19; 95% confidence interval [CI], 0.05-0.69). However, after 6 weeks, risk of relapse did not significantly differ between the 2 groups (HR, 1.18; 95% CI, 0.46-2.99).

CONCLUSIONS

Our findings demonstrate that use of SP following treatment of CMV disease did not confer long-term protection against relapse, although it did delay relapse while patients were receiving antivirals. This suggests that SP has limited clinical utility in the overall prevention of recurrent CMV disease.

摘要

背景

巨细胞病毒(CMV)是实体器官移植受者(SOTR)发病率和死亡率的主要原因。更昔洛韦和缬更昔洛韦是两种高效的抗病毒药物,在 CMV 疾病的一级预防和治疗中具有明确的作用。我们在这项研究中的目的是检查二级预防(SP)对 CMV 疾病发作后 SOTR 复发风险的影响。

方法

我们对 1995 年至 2015 年的 SOTR 进行了回顾性队列研究,并使用倾向评分逆概率治疗加权方法控制混杂因素。创建了一个加权 Cox 模型来确定 SP 对治疗完成后 1 年内复发时间的影响。

结果

52 例心脏、34 例肝脏、79 例肾脏和 5 例肝-肾移植受者完成了 CMV 感染/疾病的治疗。共有 120 例(70.6%)接受了 SP(中位数持续时间 61 天;范围 5-365 天),39 例(23%)复发。SP 在治疗完成后 0 至 6 周内对复发有保护作用(风险比[HR],0.19;95%置信区间[CI],0.05-0.69)。然而,6 周后,两组之间的复发风险无显著差异(HR,1.18;95%CI,0.46-2.99)。

结论

我们的研究结果表明,在治疗 CMV 疾病后使用 SP 并不能提供长期的复发保护,尽管它在患者接受抗病毒治疗时确实延迟了复发。这表明 SP 在预防复发性 CMV 疾病方面的临床应用有限。

相似文献

2
The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients.
Transplantation. 2015 Apr;99(4):855-9. doi: 10.1097/TP.0000000000000386.
3
The impact of recurrent cytomegalovirus infection on long-term survival in solid organ transplant recipients.
Transpl Infect Dis. 2019 Dec;21(6):e13189. doi: 10.1111/tid.13189. Epub 2019 Oct 18.
5
Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.
HPB (Oxford). 2010 Dec;12(10):657-63. doi: 10.1111/j.1477-2574.2010.00226.x.
8
Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients.
Am J Transplant. 2010 Jan;10(1):157-61. doi: 10.1111/j.1600-6143.2009.02861.x. Epub 2009 Nov 4.
9
Cytomegalovirus infection after liver transplantation: current concepts and challenges.
World J Gastroenterol. 2008 Aug 21;14(31):4849-60. doi: 10.3748/wjg.14.4849.

引用本文的文献

1
The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation.
Transplantation. 2025 Jul 1;109(7):1066-1110. doi: 10.1097/TP.0000000000005374. Epub 2025 Apr 9.
4
Cytomegalovirus infection after liver transplantation.
World J Transplant. 2020 Jul 29;10(7):183-190. doi: 10.5500/wjt.v10.i7.183.
8
A Practical Review of Cytomegalovirus in Gastroenterology and Hepatology.
Gastroenterol Res Pract. 2019 Mar 7;2019:6156581. doi: 10.1155/2019/6156581. eCollection 2019.
9
Highlights in solid transplant infectious diseases 2015-2017.
Rev Esp Quimioter. 2018 Sep;31 Suppl 1(Suppl 1):52-55.

本文引用的文献

1
Confounding by Indication in Clinical Research.
JAMA. 2016 Nov 1;316(17):1818-1819. doi: 10.1001/jama.2016.16435.
2
Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.
Clin Infect Dis. 2017 Jan 1;64(1):87-91. doi: 10.1093/cid/ciw668. Epub 2016 Sep 28.
3
Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients.
Transplantation. 2017 Jun;101(6):1449-1454. doi: 10.1097/TP.0000000000001338.
4
The Propensity Score.
JAMA. 2015 Oct 20;314(15):1637-8. doi: 10.1001/jama.2015.13480.
6
The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients.
Transplantation. 2015 Apr;99(4):855-9. doi: 10.1097/TP.0000000000000386.
8
Can the learning health care system be educated with observational data?
JAMA. 2014 Jul;312(2):129-30. doi: 10.1001/jama.2014.4364.
9
Current characteristics and outcome of cytomegalovirus infections after kidney transplantation.
Transpl Infect Dis. 2014 Aug;16(4):568-77. doi: 10.1111/tid.12247. Epub 2014 Jun 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验